Clinical trials
Lymphoma, B-Cell clinical trials
Below are recruiting lymphoma, b-cell clinical trials, each written for real people, not researchers. We’re tracking 534 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT06734871RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests an experimental drug called CT1190B for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or stopped responding to at least two prior treatments. The study aims to see if the drug can help control the disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06755775Recruiting
PET scan to predict immunotherapy success in DLBCL
This trial uses a special PET scan to see if a protein called Granzyme B can predict how well immunotherapy will work for people with DLBCL. It aims to help doctors know earlier if treatment is effective.
ShanghaiAges 18 years+ - NCT07524816Recruiting
CAR-T Cell Therapy for Relapsed Lymphoma
This trial tests an experimental CAR-T cell therapy—a treatment that uses your own immune cells modified to fight cancer—for B-cell lymphoma that has returned or stopped responding to previous treatments. Researchers are studying how well this therapy works in real-world practice.
Lyasny, Minsk OblastAges 18–80 - NCT07523555RecruitingPhase 1/Phase 2
Dual-Target CAR-T Cells for Blood Cancers That Haven't Responded to Treatment
This study tests a new type of cell therapy called CAR-T cells that are designed to target two different proteins on cancer cells. These cells are made from your own immune cells, trained in the lab, and then put back into your body to fight blood cancers that have come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07520006RecruitingPhase 1/Phase 2
NX-5948 With Other Drugs for B-cell Blood Cancers
This early-stage study tests a new drug called NX-5948, given alongside other cancer treatments, for adults with B-cell lymphomas and leukemias (including chronic lymphocytic leukemia, or CLL). The goal is to see if this combination helps control the disease, especially in patients whose cancer has come back or stopped responding to prior treatments.
Aurora, ColoradoAges 18 years+ - NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+ - NCT07523737RecruitingPhase 2
Combination drug trial for relapsed brain lymphoma
This trial tests three drugs together—pomalidomide, an anti-PD-1 antibody, and selinexor—to treat primary central nervous system lymphoma (a blood cancer in the brain) that has returned after previous treatment. The goal is to see if this combination can shrink the cancer and help patients live longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT05054257RecruitingPhase 1
CAR T19 for hard-to-treat blood cancers that have CD19
This Phase 1 study tests CAR T cells designed to attack cancer cells that carry a marker called CD19. It’s for adults with certain relapsed or treatment-resistant B-cell leukemias (ALL) or lymphomas (NHL) where other treatments may not have worked.
PragueAges 18–80 - NCT07516093RecruitingPhase 3
Comparing two drugs for advanced CLL or SLL
This trial tests whether NX-5948 is more effective than pirtobrutinib for people with CLL or SLL whose disease has gotten worse after an earlier BTK inhibitor treatment. It aims to find a better option for those who have already tried one type of therapy.
Macon, GeorgiaAges 18 years+ - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07508605RecruitingPhase 1/Phase 2
CD19/CD20 CAR/TRuC-T cells for lymphoma that returned or didn't respond
This trial tests a new type of immune cell therapy that targets two markers (CD19 and CD20) on your lymphoma cells. It is for people whose lymphoma came back or didn't respond to previous treatments, including CD19 CAR-T therapy.
Shenzhen, GuangdongAges 18–75 - NCT07514169RecruitingPhase 2
New Combination Drug for Older Adults with B-Cell Lymphoma
This study tests whether a new three-drug combination (Pola-ZR-Glo) works safely and effectively for older adults with a type of blood cancer called large B-cell lymphoma who cannot or prefer not to receive standard chemotherapy. The goal is to find a gentler treatment option for frail or elderly patients.
ShanghaiAges 70 years+ - NCT07502118RecruitingPhase 2/Phase 3
NexCAR19 for B-cell blood cancers that came back
This trial tests NexCAR19 (a CAR-T cell therapy) for people with certain types of B-cell lymphoma or B-cell acute lymphoblastic leukemia that didn't respond to or came back after other treatments. It aims to see if this therapy can help control the cancer.
AnkaraAges 18 years+ - NCT07507318RecruitingPhase 2
Low-dose chemo to prevent relapse in high-risk DLBCL patients
This trial tests a low-dose chemotherapy pill (chidamide) for people with a certain high-risk type of DLBCL that still has signs of cancer in the blood after initial treatment. The goal is to keep the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07499271RecruitingPhase 2
Targeted therapy for newly diagnosed DLBCL with TP53 mutation
This trial tests a targeted therapy designed to match the specific genetic subtype of DLBCL that has a TP53 mutation. It may offer a more effective treatment option for people whose cancer has this genetic change.
Suzhou, JiangsuAges 18–70 - NCT07493109RecruitingPhase 3
Maintenance treatment for hepatitis B-related lymphoma after initial therapy
This trial tests whether the drug chidamide, taken after initial successful treatment, can help prevent relapse in people with a type of lymphoma (diffuse large B-cell lymphoma) who also have chronic hepatitis B. Participants must have achieved complete remission after six cycles of standard chemotherapy (R-CHOP).
Changchun, JilinAges 18–80 - NCT07493148RecruitingPhase 2
Chidamide and chemo for older adults with double-expressor DLBCL
This trial tests a combination of the targeted drug chidamide with a gentler chemotherapy (R-mini CHOP) followed by maintenance therapy for people aged 70 or older with a specific type of DLBCL that has both MYC and BCL2 proteins. It aims to improve outcomes while reducing side effects.
Changchun, JilinAges 70 years+ - NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07489989RecruitingPhase 2
Combination therapy to boost CAR-T for B-cell lymphoma
This trial tests a new combination of drugs to make CAR-T cell therapy work better for people with certain types of B-cell lymphoma. It adds the drugs chidamide and a PD-1 inhibitor to the usual CAR-T treatment, aiming to improve response.
Beijing, Beijing MunicipalityAges 18–85 - NCT05281809RecruitingPhase 2
CAR T-cell therapy made locally for B-cell blood cancers
This Phase 2 trial tests a locally manufactured CAR T-cell treatment for certain B-cell lymphomas and B-ALL that have limited treatment options left. It may help your immune system attack cancer cells that carry the CD19 marker, potentially as a bridge to transplant for some patients.
Pittsburgh, PennsylvaniaAges 18–79 - NCT06774326Recruiting
Spectral CT to check for heart damage from lymphoma treatment
This study uses a special type of CT scan called spectral CT to see if chemotherapy drugs called anthracyclines can cause heart damage in people with certain lymphomas. The goal is to catch any heart problems early by imaging the heart before, during, and after treatment.
BolognaAges 18 years+ - NCT07479797RecruitingPhase 3
Comparing two CAR T-cell therapies for large B-cell lymphoma after first treatment
This trial tests a new CAR T-cell therapy, KITE-753, against an approved one, Yescarta (axicabtagene ciloleucel), for people with large B-cell lymphoma that came back or didn't respond to first-line treatment. The goal is to see which works better.
Goodyear, ArizonaAges 18 years+ - NCT07473167RecruitingPhase 1/Phase 2
Study of TC011 for large B-cell lymphoma that has not responded to treatment
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Seoul, SeoulAges 19 years+
Hear when a new Lymphoma, B-Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma, b-cell?
- Yes. Clin2 currently lists 534 recruiting lymphoma, b-cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma, b-cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma, b-cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.